Epidemiology and treatment of head and neck malignancies in the AYA generation [0.03%]
青年期内头颈部恶性肿瘤的流行病学和治疗
Takahiro Asakage
Takahiro Asakage
The Adolescent and Young Adult (AYA) population refers to the population of young adults and adolescents in the 15-39 years age group. This population subgroup experiences various important life events. Head and neck malignancies are rare t...
Hormone replacement therapy in relation to the risk of colorectal cancer in women by BMI: a multicentre study with propensity score matching [0.03%]
体重指数与雌激素替代疗法和结直肠癌风险关系的多中心研究--倾向性匹配分析
Lingkai Xu,Lin Li,Dongkui Xu et al.
Lingkai Xu et al.
Background: Epidemiological evidence about hormone replacement therapy and colorectal carcinogenesis by demographic and clinical traits remains unclear. We aimed to assess this postulated association in a large multicentr...
Japan Society of Clinical Oncology Clinical Practice Guidelines 2017 for fertility preservation in childhood, adolescent, and young adult cancer patients: part 2 [0.03%]
日本临床肿瘤学会儿童、青少年及年轻成人癌症患者生育力保存临床实践指南2017（下）
Akiko Tozawa,Fuminori Kimura,Yasushi Takai et al.
Akiko Tozawa et al.
The Japan Society of Clinical Oncology (JSCO) published the "JSCO Clinical Practice Guidelines 2017 for Fertility Preservation in Childhood, Adolescent, and Young Adult Cancer Patients" in 2017. This was the first guideline in cancer reprod...
Mapping of global, regional and national incidence, mortality and mortality-to-incidence ratio of lung cancer in 2020 and 2050 [0.03%]
2020和2050年全球、区域及国家层面的肺癌发病与死亡_mappings及死亡率_mapping
Rajesh Sharma
Rajesh Sharma
Aim: Lung cancer is the leading cause of cancer deaths worldwide. This study examines the current and future burden of lung cancer at global, regional, and national levels. ...
Status of cervical cancer screening among adolescents and young adults (AYA) in Japan [0.03%]
日本青少年和青年人宫颈癌筛查现状
Eiko Saitoh,Kumiko Saika,Tohru Morisada et al.
Eiko Saitoh et al.
Cervical cancer ranks high among the cancers that affect people in their 20s and 30s. Cervical cancer is characterized by the presence of precancerous lesions, which can be detected by cancer screenings; some precancerous lesions are amenab...
Novel combined fibrosis-based index predicts the long-term outcomes of hepatocellular carcinoma after hepatic resection [0.03%]
新型联合纤维化指标用于预测肝切除术后肝细胞癌远期结局
Mitsuru Yanagaki,Yoshihiro Shirai,Ryoga Hamura et al.
Mitsuru Yanagaki et al.
Aim: Liver fibrosis influences liver regeneration and surgical outcomes. The fibrosis-4 (FIB-4) index is strongly associated with liver fibrosis and cirrhosis. This study aimed to examine the prognostic significance of th...
Relationship between psoas muscle index and long-term survival in older patients aged ≥ 80 years after endoscopic submucosal dissection for gastric cancer [0.03%]
老年患者胃癌内镜黏膜下剥离术后长期生存与腰大肌指数之间的关系（≥80岁）
Nobuhito Ito,Kohei Funasaka,Ryoji Miyahara et al.
Nobuhito Ito et al.
Background: In Japan, endoscopic submucosal dissection (ESD) has been widely performed for ESD-adapted gastric cancer, but little is known about the prognostic factors after ESD for gastric cancer in older patients. The p...
Male patients with papillary thyroid cancer have a higher risk of extranodal extension [0.03%]
男性乳头状甲状腺癌患者淋巴结外侵犯的风险更高
Hu Hei,Bin Zhou,Wenbo Gong et al.
Hu Hei et al.
Background: There is a sex disparity in papillary thyroid cancer (PTC). Male sex is associated with a higher likelihood of advanced stage disease. This study aimed to examine the significance of sex for extranodal extensi...
Platinum rechallenge treatment using gemcitabine plus carboplatin with or without bevacizumab for platinum-resistant ovarian cancer [0.03%]
含卡铂、吉西他滨单药或联合贝伐珠单抗治疗对铂类耐药卵巢癌的疗效分析
Hiroki Nasu,Shin Nishio,Jongmyung Park et al.
Hiroki Nasu et al.
Purpose: Platinum-resistant ovarian cancer (PROC) is usually treated with single-agent chemotherapy. A synergistic effect of gemcitabine and platinum has been reported in PROC. We evaluated the efficacy and safety of gemc...
Avelumab first-line maintenance plus best supportive care (BSC) vs BSC alone for advanced urothelial carcinoma: JAVELIN Bladder 100 Japanese subgroup analysis [0.03%]
阿维鲁单抗联合最佳支持治疗对比单纯最佳支持治疗一线维持治疗晚期尿路上皮癌的日本患者亚组分析：JAVELIN Bladder 100研究
Yoshihiko Tomita,Yoshiaki Yamamoto,Norihiko Tsuchiya et al.
Yoshihiko Tomita et al.
Background: The phase 3 JAVELIN Bladder 100 trial showed significantly prolonged overall survival (OS) with avelumab as first-line (1L) maintenance therapy + best supportive care (BSC) vs BSC alone in patients with advanc...
Randomized Controlled Trial
International journal of clinical oncology. 2022 Feb;27(2):383-395. DOI:10.1007/s10147-021-02067-8 2022